My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares (NQ:KNSA)

38.76 -0.16 (-0.41%)
Streaming Delayed Price Updated: 3:53 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

< Previous 1 2 3 4 Next >
5 Analysts Have This To Say About Kiniksa Pharmaceuticals
 
Via Benzinga
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Identified by High Growth Momentum and Minervini Trend Screen
Kiniksa Pharma (KNSA) is a high-growth momentum stock in a strong technical uptrend, with surging earnings and sales supporting its price advance. 
Via Chartmill
What Analysts Are Saying About Kiniksa Pharmaceuticals Stock
4 analysts have expressed a variety of opinions on Kiniksa Pharmaceuticals (NASDAQ: KNSA) over the past quarter, offering a diverse set of opinions from bullish to bearish. 
Via Benzinga
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shows High-Growth Momentum and Strong Technical Setup
Kiniksa Pharmaceuticals (KNSA) shows explosive EPS growth of 483% and strong technicals, trading near 52-week highs in a consolidation pattern that suggests a potential breakout. 
Via Chartmill
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Emerges as an Affordable Growth Opportunity
Kiniksa Pharmaceuticals (KNSA) offers strong growth potential at a reasonable valuation. With 125% EPS growth, no debt, and a forward P/E of 21.47, it's a compelling affordable growth stock. 
Via Chartmill
Earnings Scheduled For July 29, 2025
 
Via Benzinga
Earnings Preview: Kiniksa Pharmaceuticals
 
Via Benzinga
Earnings Scheduled For April 29, 2025
 
Via Benzinga
Earnings Scheduled For February 25, 2025
 
Via Benzinga
Exploring Kiniksa Pharmaceuticals's Earnings Expectations
 
Via Benzinga
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Top Affordable Growth Candidate
Kiniksa Pharma (KNSA) is a strong affordable growth stock with impressive revenue & EPS growth, a reasonable valuation, and a solid debt-free balance sheet. 
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Exhibits High Growth Momentum and Technical Breakout Potential
Kiniksa Pharma (KNSA) shows strong earnings growth and a bullish technical setup, making it a high-growth momentum stock to watch for a potential breakout. 
Via Chartmill
KINIKSA PHARMACEUTICALS INTE (NASDAQ:KNSA): A Strong Growth Stock with a Positive Technical Breakout
Kiniksa Pharma (KNSA) is a strong growth stock with 125% EPS growth, a debt-free balance sheet, and a bullish technical breakout pattern. 
Via Chartmill
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) – An Affordable Growth Stock with Strong Fundamentals and Fair Valuation
Affordable Growth investing targets stocks like Kiniksa Pharmaceuticals (KNSA), balancing strong revenue/earnings growth with fair valuations and financial health. KNSA shows high growth (8/10), solid... 
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Aligns with Minervini’s Trend Model as a Strong Momentum Pick
Kiniksa Pharmaceuticals (KNSA) aligns with Minervini’s Trend Model, showing strong technicals, rapid earnings growth, and upward momentum—ideal for growth investors. 
Via Chartmill
Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?
The upgraded score means Gilead is now outperforming 96% of all stocks in terms of the most important stock-picking criteria. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them? 
Via Benzinga
Topics Artificial Intelligence
Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis
From Kiniksa Pharmaceuticals, Ltd.
Via GlobeNewswire
These stocks are gapping in today's session
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Honeywell Posts Better-Than-Expected Q1 Earnings, Joins Crown Holdings, Noble, Crane And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Examining the Future: Kiniksa Pharmaceuticals's Earnings Outlook
 
Via Benzinga
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
Via The Motley Fool
Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst
Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
– Life DisRPted is an educational campaign aimed at promoting early diagnosis and treatment of recurrent pericarditis, a painful and debilitating chronic autoinflammatory disease – 
From Kiniksa Pharmaceuticals, Ltd.
Via GlobeNewswire
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.